Atossa Therapeutics Inc (ATOS)

• $1.31

  $1.37

  $1.33
  

  1.88%

  Downside

  Day's Volatility :4.68%

  Upside

  2.86%

  
• $0.62

  $2.31

  $1.33
  

  53.38%

  Downside

  52 Weeks Volatility :73.16%

  Upside

  42.42%

  

Returns

What analysts predicted

Upside of 307.52%

• BlackRock Inc

  7.31%

• Vanguard Group Inc

  5.16%

• Renaissance Technologies Corp

  1.10%

• Geode Capital Management, LLC

  0.96%

• Morgan Stanley - Brokerage Accounts

  0.61%

• State Street Corporation

  0.39%

atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.